Disease Modeling

Our expertise in disease modeling

CYTOO develops physiologically relevant and robust in vitro models of skeletal muscle diseases using patient-derived cells. Our disease models recapitulate key pathological hallmarks and are designed to bridge discovery and translation towards the clinic.

Our approach

We combine our MyoScreen platform with deep biological insights, high-content cellular imaging and advanced data science.

Our data-driven phenotypic analysis, powered by machine learning and statistical modeling, enables the detection of subtle and complex disease-related features that are beyond the reach of conventional methods.

Automated image acquisition and processing workflows ensure scalability, reproducibility and throughput for drug discovery applications.

Our platform also supports multi-modal molecular readouts including RT-qPCR, RNA-seq and other omics approaches, enabling comprehensive characterization of disease models.

Case study

The DM1 MyoScreen platform

Myotonic dystrophy type 1 (DM1) MyoScreen platform based on patient derived myoblasts recapitulating key pathological hallmarks —including DMPK RNA foci, MBNL1 mislocalization, splicing defects, and altered calcium signaling.

Quantitative, image-based assays available to evaluate therapeutic rescue. Splicing correction across multiple target genes can also be assessed.

Successfully integrated into multiple partner programs supporting drug discovery across various therapeutic modalities, including gene therapies, small molecules, and oligonucleotides.

How can we work together

Everything is tailored to your needs through a flexible R&D partnership model that fosters true collaboration and innovation. We offer adaptable project structures and FTE allocation to fit your goals.

In cases of joint development, outlicensing opportunities are also available for our MyoScreen™ technology, including assays and customised image analysis scripts.